Rare Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have a condition called calciphylaxis, with at least one wound that is open (ulcerated) or has tissue that has died (necrotic)
- You have end-stage kidney disease and are currently receiving hemodialysis (kidney dialysis)
- You weigh more than 30 kg (approximately 66 pounds)
- You are covered by a social security or health insurance system
- You are willing and able to sign a written consent form agreeing to take part
- You may also be eligible if your calciphylaxis has been getting worse — developing open wounds or tissue death — despite already receiving standard treatment
Who may not be able to join:
- Your overall physical ability and health is very severely reduced, based on a specific medical scoring scale (confirm with trial site)
- Your doctor who specialises in dialysis estimates that, for reasons unrelated to calciphylaxis, you are not expected to live more than 6 months
- You have an infection that cannot be controlled, meaning you still have a fever even after receiving appropriate antibiotic treatment
- You have a condition called common variable immunodeficiency, which affects how your immune system works
- You have a known allergy to albumin (a protein used in some medical treatments)
- You are taking a type of blood-thinning medication called anti-vitamin K, and it would not be safe for you to stop taking it
- You have severe cognitive (thinking/memory) or psychiatric (mental health) difficulties that prevent you from giving informed consent, or you are unwilling to participate
- You are pregnant or breastfeeding
- You are under legal supervision, are hospitalised without your consent, are living in a care facility where you are receiving care rather than participating in research, or are in an emergency situation (these are specific protections under French health law)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Arnaud Lionet, MD, University Hospital, Lille
Phone: 0320445000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of patients with complete wound healing of the calciphylaxis-mediated ischemic lesions after 12 weeks of rheopheresis treatment (a total of 17 sessions).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.